ID   DU528
AC   CVCL_5617
SY   DU-528; Du-528; DU.528; Duke University 528
DR   Cosmic; 913423
DR   Cosmic; 1115590
DR   Cosmic; 1151778
DR   Cosmic; 1281367
DR   Cosmic; 2602913
DR   IARC_TP53; 21651
DR   Wikidata; Q54831579
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=2144611;
RX   PubMed=2740341;
RX   PubMed=4056659;
RX   PubMed=15472075;
RX   PubMed=17117183;
RX   PubMed=17170727;
WW   https://humantallcelllines.wordpress.com/comprehensivetable/du-528/
CC   Doubling time: 48-72 hours (PubMed=4056659); 40 hours (PubMed=17117183).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=2144611).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
DI   NCIt; C7953; Childhood T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   16Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 17
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=2144611; DOI=10.1128/mcb.10.10.5502-5509.1990;
RA   Cheng J., Haas M.;
RT   "Frequent mutations in the p53 tumor suppressor gene in human leukemia
RT   T-cell lines.";
RL   Mol. Cell. Biol. 10:5502-5509(1990).
//
RX   PubMed=2740341; DOI=10.1073/pnas.86.13.5039;
RA   Finger L.R., Kagan J., Christopher G., Kurtzberg J., Hershfield M.S.,
RA   Nowell P.C., Croce C.M.;
RT   "Involvement of the TCL5 gene on human chromosome 1 in T-cell leukemia
RT   and melanoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:5039-5043(1989).
//
RX   PubMed=4056659; DOI=10.1084/jem.162.5.1561;
RA   Kurtzberg J., Bigner S.H., Hershfield M.S.;
RT   "Establishment of the DU.528 human lymphohemopoietic stem cell line.";
RL   J. Exp. Med. 162:1561-1578(1985).
//
RX   PubMed=15472075; DOI=10.1126/science.1102160;
RA   Weng A.P., Ferrando A.A., Lee W., Morris J.P. IV, Silverman L.B.,
RA   Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C.;
RT   "Activating mutations of NOTCH1 in human T cell acute lymphoblastic
RT   leukemia.";
RL   Science 306:269-271(2004).
//
RX   PubMed=17117183; DOI=10.1038/sj.bjc.6603447;
RA   Beesley A.H., Palmer M.-L., Ford J., Weller R.E., Cummings A.J.,
RA   Freitas J.R., Firth M.J., Perera K.U., de Klerk N.H., Kees U.R.;
RT   "Authenticity and drug resistance in a panel of acute lymphoblastic
RT   leukaemia cell lines.";
RL   Br. J. Cancer 95:1537-1544(2006).
//
RX   PubMed=17170727; DOI=10.1038/sj.leu.2404486;
RA   Sandberg Y., Verhaaf B., van Gastel-Mol E.J., Wolvers-Tettero I.L.M.,
RA   de Vos J., MacLeod R.A.F., Noordzij J.G., Dik W.A., van Dongen J.J.M.,
RA   Langerak A.W.;
RT   "Human T-cell lines with well-defined T-cell receptor gene
RT   rearrangements as controls for the BIOMED-2 multiplex polymerase chain
RT   reaction tubes.";
RL   Leukemia 21:230-237(2007).
//